临床试验/NCT00040469

NCT00040469终止2 期

Allogeneic Bone Marrow Transplant From HLA Identical Related Donors for Patients With High Risk Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, Hemoglobin SB0/+ Thalassemia, or Homozygous B0/+ Thalassemia or Severe Variants of B0/+ Thalassemia

Baylor College of Medicine2 个研究点分布在 1 个国家目标入组 15 人开始时间: 2000年8月1日最近更新: 2020年1月18日

适应症

试验速览

阶段: 2 期
状态: 终止
发起方: Baylor College of Medicine
入组人数: 15
试验地点: 2

研究概览研究设计入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.

详细描述

To do the bone marrow transplant, we must first kill the cells in the bone marrow that make the abnormal red blood cells that are found in patients with severe thalassemia or sickle cell disease.

We will do this by using three drugs: busulfan, cyclophosphamide, and CAMPATH-1H. CAMPATH-IH is an investigational drug. CAMPATH-1H is used to prevent participants from rejecting or refusing to let the donor blood cells grow in the body. After the drug treatment, participants will be given bone marrow from a brother or sister who has healthy bone marrow that matches.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 1 Day 至 64 Years（Child, Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients with homozygous B0/+ thalassemia or severe variants of B0/+ thalassemia with an HLA genotypically identical donor.
•Patients with an HLA genotype identical donor and hemoglobin SS, hemoglobin SC, or hemoglobin Sb 0/+ and at least one of the following:
•Previous central nervous system vaso-occlusive episode with or without residual neurologic findings; Frequent painful vaso-occlusive episodes which significantly interfere with normal life activities and which necessitate chronic transfusion therapy; Recurrent SCD chest syndrome events which necessitate chronic transfusion therapy.
•Severe anemia which prevents acceptable quality of life and necessitates chronic transfusion therapy.
•The patient must have an HLA genotype identical donor.
•Between the ages of birth and 65 years.
•Women of childbearing potential must have a negative pregnancy test.

排除标准

•Biopsy proven chronic active hepatitis or fibrosis with portal bridging.
•SCD chronic lung disease >/= stage
•Severe renal dysfunction defined as creatinine clearance <40 ml/min/1.73 M2
•Severe cardiac dysfunction defined as shortening fraction <25%.
•HIV infection.
•Severe but unspecified chronic toxicity serious enough to detrimentally affect the patient's capacity to tolerate bone marrow transplant (BMT).
•Inadequate intellectual capacity to understand the nature and risk inherent in the BMT process and give informed consent (in the case of minors, this criteria must be fulfilled by the legal guardian).
•Pregnant, lactating or unwilling to use appropriate birth control.

研究者

发起方

Baylor College of Medicine

申办方类型

Other

责任方

Principal Investigator

主要研究者

Robert Krance

Professor

Baylor College of Medicine

研究点 (2)

Loading locations...

相似试验

已完成

不适用

Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic DisordersNeutropeniaRed-Cell Aplasia, PureSickle Cell AnemiaThalassemia Major

NCT00005893Fairview University Medical Center

已完成

不适用

NCT01364363Scripps Health64

撤回

1 期

Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn'sAnal FistulaPouch, IlealPouches, IleoanalFistulaCrohn's Disease

NCT04073472The Cleveland Clinic

招募中

2 期

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary ImmunodeficienciesCommon Variable ImmunodeficiencyPrimary T-cell Immunodeficiency DisordersImmune System DiseasesAutoimmune LymphoproliferativeLymphoproliferative Disorders

NCT02579967National Cancer Institute (NCI)354

终止

不适用

Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected PatientsHIV-1 Infection

NCT02732457Kirby Institute5